The global antiviral drugs market size was valued at USD 56.06 billion in 2025 and is projected to grow from USD 57.35 billion in 2026 to USD 68.85 billion by 2034, registering a CAGR of 2.31% during the forecast period (2026-2034). North America dominated the antiviral drugs market with a share of 33.51% in 2025.
Antiviral drugs are medicines designed to interfere with specific stages of viral replication, helping control infections and reduce the severity or duration of illness. They are commonly classified under HSN Code 3004 (medicaments for therapeutic or prophylactic uses, put up in measured doses or retail packaging) and SIC Code 2834 (Pharmaceutical Preparations).
The antiviral drugs market demand is driven by the continued burden of viral infections, and the need for effective treatments against both chronic and acute viral diseases. Healthcare providers are increasingly using reverse transcriptase inhibitors, direct-acting antivirals, and broad-spectrum antiviral therapies to suppress viral replication and manage infections.
Download a Free Sample To learn more about this report,
Shift toward Broad Spectrum Antiviral Drug Development
The antiviral drugs market analysis shows shift towards broad spectrum antiviral drug development to address multiple viral infections using a single therapeutic approach. Researchers are developing compounds that target viral replication mechanisms or essential stages of viral life cycles shared by different viruses.
Adoption of Direct Acting Antiviral Therapies
Advances in antiviral research are shaping the antiviral drugs market through the growth of direct acting antiviral therapies that target specific viral proteins or enzymes required for replication. These treatments can interfere with viral multiplication and improve disease management, particularly in conditions such as hepatitis C.
Supply chain disruptions are expected to have a moderate impact on the antiviral drugs market share due to dependence on active pharmaceutical ingredients, specialized chemical compounds, and formulation materials. The market is expected to follow a stair-step recovery, as shortages of drug ingredients, manufacturing delays, and disruptions in pharmaceutical distribution can affect medicine availability. The market is expected to grow at a CAGR of 2.31%, but supply chain constraints could lower this by 0.5 percentage points, resulting in a growth of around 1.81%. As supply conditions normalize, the antiviral drugs market growth is expected to gradually return to 2.31%.
The antiviral drugs market forecasts strategic investment activity driven by the development of advancement of RNA-based treatments, research into drugs targeting emerging and pandemic-prone viruses, and expansion of clinical development programs. In August 2026, Lumen Bioscience received funding of up to USD 7 million from the U.S. Department of War to support Phase 1 clinical development of LMN-1001.
Rise in Incidence of HIV and Chronic Hepatitis Infections and Investment in Pandemic Preparedness and Response Drives Market
High burden of HIV and chronic hepatitis infections is supporting the growth of the antiviral drug market by increasing the need for long-term disease management. Patients with these infections often require ongoing antiviral therapy to control viral replication, reduce complications, and improve health outcomes. Wider access to testing and treatment programs is also helping more patients receive appropriate medicines.
Investments in pandemic preparedness and response are driving the antiviral drugs market by supporting research into new treatments for existing and emerging viral threats. These initiatives encourage the development of antiviral medicines with broader applications and improve treatment availability during public health emergencies, supporting market growth.
Stringent Regulatory Approval Requirements and Limited Effectiveness Against Emerging Viral Strains Restrain Market Expansion
Stringent regulatory approval requirements create challenges for the antiviral drugs market due to the extensive clinical testing, safety assessments, and efficacy data required before new drugs can be commercialized. These processes increase development costs and extend approval timelines, delaying the availability of new treatments.Limited effectiveness against emerging viral strains remains a key restraint in the antiviral drug market because viruses can undergo genetic changes that reduce their sensitivity to existing treatments. Such changes may lower drug effectiveness and increase the need for updated therapies or combination treatments.
Expansion of Antiviral Treatments for Immunocompromised Patients and Long-Acting Antiviral Formulations Offer Growth Opportunities
Antiviral drug developers are focusing on immunocompromised patients undergoing cancer treatment, organ transplantation, or immunosuppressive therapy. They face an elevated risk of severe or prolonged viral infections. The US CDC identifies immunocompromised individuals as a high-risk group for severe disease and recommends prompt assessment for eligible antiviral treatment, supporting the need for therapies tailored to vulnerable patient populations.
Drug manufacturers and biotechnology companies can target healthcare providers and patients seeking alternatives to frequent antiviral dosing. Long-acting formulations, including extended-release injections and other sustained-delivery approaches, can help reduce dosing frequency for selected viral infections.
Reverse transcriptase inhibitors accounted for the largest share of 31.74%, driven by their established role in antiretroviral therapy for managing HIV infections. These drugs inhibit viral replication by interfering with the reverse transcriptase enzyme.
The capsid inhibitors segment is projected to grow at a CAGR of 6.28% during the forecast period, supported by the development of therapies that target the viral capsid and interfere with different stages of the HIV life cycle.
Request Customizationto receive a tailored report.
HIV dominated the application segment with a share of 40.26% in 2025, owing to the widespread use of antiviral drugs for long-term infection management. Continued demand for antiretroviral therapy supports the use of multiple drug classes to suppress viral replication and maintain treatment outcomes.
Respiratory syncytial virus segment is expected to achieve a growth rate of 5.63% during the forecast period, driven by the need for effective treatment options for high-risk populations, including infants and older adults.
Hospital pharmacies accounted for the share of 42.73%, supported by their role in dispensing antiviral medications through hospitals and specialized treatment programs.
Oline pharmacy segment is anticipated to record a growth rate of 4.68% during the forecast period, driven by increasing adoption of digital pharmacy services and convenient home delivery. Online platforms can improve access to eligible prescription antiviral medicines, subject to applicable regulations and prescription requirements.
Speak to an Analystto discuss market opportunities.
The North America antiviral drugs market accounted for a dominant share of 33.51% in 2025.
U.S. Centers for Disease Control and Prevention recommends four influenza antivirals for the current flu season: oseltamivir, zanamivir, peramivir, and baloxavir. The inclusion of baloxavir, a single-dose oral treatment for uncomplicated influenza, highlights the continued role of different antiviral treatment options in influenza management.
Canada’s provincial and territorial drug programs provide coverage for HIV antiretroviral medications, with coverage arrangements varying by jurisdiction. The Public Health Agency of Canada has documented these differences in its national review of antiretroviral drug coverage, highlighting the role of public reimbursement programs in access to long-term HIV antiviral treatments.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific antiviral drugs market is projected to grow at a CAGR of 4.08% during the forecast period, making it the fastest-growing region.
China’s National Health Commission issued an updated influenza diagnosis and treatment protocol, refining antiviral treatment principles and clinical management recommendations. The update specifically addresses the use of influenza antivirals, reflecting continued efforts to standardise treatment for seasonal respiratory virus infections.
Indian Council of Medical Research (ICMR) invited expressions of interest for the technology transfer of an RNA interference (RNAi)-based therapeutic candidate targeting chikungunya, creating a pathway for further development and potential commercialisation. The government’s Production Linked Incentive (PLI) scheme for bulk drugs has an outlay of ₹6,940 crore through FY 2028–29 to strengthen domestic production of critical pharmaceutical ingredients and reduce import dependence.
Japan has seen the clinical use of glecaprevir and pibrentasvir, a combination of direct-acting antiviral agents used to treat chronic hepatitis C infection. The combination targets viral proteins essential for hepatitis C replication and offers an oral treatment course, reflecting the shift toward targeted antiviral therapies for chronic viral infections.
Europe's antiviral drugs market is likely to grow at a CAGR of 2.12% during the forecast period.
German Center for Infection Research (DZIF) has conducted clinical studies on bulevirtide, an antiviral treatment for chronic hepatitis D, a serious viral infection that can occur alongside hepatitis B. The clinical research focuses on treatment response and identifying biomarkers that could help determine when therapy can be safely stopped, highlighting ongoing work to improve treatment approaches for difficult-to-treat viral infections.
UK Health Security Agency expanded whole-genome sequencing surveillance for hepatitis C to monitor antiviral resistance and identify harder-to-treat viral strains. The programme examines resistance patterns affecting direct-acting antivirals, including NS3, NS5A, and NS5B inhibitors, demonstrating the growing importance of resistance monitoring in hepatitis antivirals treatment.
The Latin America antiviral drugs market will expand to 2.63% CAGR during the forecast period. Brazil is participating in the development of EYU688, an investigational oral antiviral designed to inhibit dengue virus replication across all four serotypes. A Phase IIa clinical trial has evaluated its safety and efficacy in dengue patients, with clinical trial sites in Brazil including Manaus, Brasília, and Rio de Janeiro. Mexican Social Security Institute (IMSS) also reported that over 90% of its patients receiving HIV treatment were using modern combination regimens in a single daily tablet.
The Middle East & Africa antiviral drugs market is estimated to register a growth rate of 2.74% during the forecast period. A clinical position paper developed by UAE-based specialists examined strategies for preventing and managing respiratory infections in high-risk patients. It addressed the use of antiviral agents against respiratory viruses and highlighted gaps in treatment practices for vulnerable groups. South Africa registered lenacapavir as a long-acting antiviral medicine for HIV prevention. Administered by injection twice yearly, the drug represents a newer approach to preventing HIV infection compared with daily oral preventive medicines.
The antiviral drugs market competitive landscape is highly fragmented, with established pharmaceutical companies, biotechnology firms, and specialized antiviral drug developers. Key players such as F. Hoffmann-La Roche, Gilead Sciences, Merck, Pfizer, and AbbVie are estimated to account for 35–40% of the global antiviral drugs market share.
Established players compete mainly through antiviral drug development, treatment efficacy, and broad-spectrum antiviral therapies. Emerging and regional players in the antiviral drugs market ecosystem focus on targeted therapies, novel antiviral mechanisms and specialized treatments for different viral infections.
June 2026: Shionogi received U.S. FDA approval for XOCOVA (ensitrelvir) to help prevent symptomatic COVID-19 following exposure in adults and adolescents aged 12 years and older.
September 2026: NanoViricides began enrolling and dosing patients in a Phase II clinical trial of its investigational broad-spectrum antiviral candidate NV-387 for mpox in the Democratic Republic of the Congo.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Autosomal Dominant Polycystic Kidney Disease Market Size, Forecast, 2034
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
Chemotherapy Induced Thrombocytopenia Market Size, Forecast, Opportunities, 2034
Chronic Venous Occlusions Treatment Market Size, Demand, Opportunities, 2034
Cardiometabolic Disease Market Size, Share, Growth, Analysis, 2034
Clot Busting Drugs Market Size, Forecast, Demand, Opportunities, 2034
We are featured on:
sales@straitsresearch.com